临床医学工程2023，Vol.30Issue(12)：1705-1706,2.DOI:10.3969/j.issn.1674-4659.2023.12.1705
替雷利珠单抗联合经肝动脉化疗栓塞治疗晚期肝癌的临床研究
Clinical Study of Telalipizumab Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Liver Cancer
袁生武 1刘凯1
作者信息
- 1. 郑州大学第五附属医院介入科,河南郑州 450052
- 折叠
摘要
Abstract
Objective To explore the effect of telalipizumab combined with transcatheter arterial chemoembolization(TACE)in the treatment of advanced liver cancer.Methods 72 patients with advanced liver cancer were randomly divided into two groups,with 36 cases in each group.The control group was treated with TACE,and the observation group was treated with telalipizumab at 3～5 days after surgery on the basis of the control group.The therapeutic effect,serum indicators and adverse reactions were compared between the two groups.Results The disease control rate of the observation group was higher than that of the control group(P＜0.05).After treatment,the levels of VEGF and AFP of the observation group were lower than those of the control group(P＜0.05).No significant difference was found in the incidences of adverse drug reactions between the two groups(P＞0.05).Conclusions TACE combined with telalipizumab treatment can improve the disease control rate of advanced liver cancer,inhibit the expressions of VEGF and AFP,and has high treatment safety.关键词
替雷利珠单抗/经肝动脉化疗栓塞/晚期肝癌Key words
Telalipizumab/Transcatheter arterial chemoembolization/Advanced liver cancer分类
医药卫生引用本文复制引用
袁生武,刘凯..替雷利珠单抗联合经肝动脉化疗栓塞治疗晚期肝癌的临床研究[J].临床医学工程,2023,30(12):1705-1706,2.
